{"id":71388,"date":"2026-05-20T08:30:59","date_gmt":"2026-05-20T08:30:59","guid":{"rendered":"https:\/\/medsbase.com\/ara-290\/"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"ara-290","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/ara-290\/","title":{"rendered":"ARA-290 (Cibinetide)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u00e9ponse rapide \u2014 Qu'est-ce que l'ARA-290 ?<\/h3>\n<p style=\"margin: 0;\"><strong>ARA-290<\/strong> (cibinetide; Helix B Surface Peptide, HBSP) is an 11-amino-acid synthetic peptide derived from helix B of erythropoietin (EPO). Designed by Brines &amp; Cerami to dissociate EPO&#8217;s cytoprotective effects from its erythropoietic effects, ARA-290 binds the innate repair receptor (IRR) \u2014 a heterocomplex of the EPO receptor and the beta-common receptor (CD131) \u2014 and triggers anti-inflammatory, anti-apoptotic, and tissue-repair signalling without elevating red-cell mass. Developed by Araim Pharmaceuticals; orphan-designated for sarcoidosis-associated small-fiber neuropathy. Supplied in 10 mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1208243-50-8 (cibinetide)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Type<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Peptide synth\u00e9tique de 11 acides amin\u00e9s non \u00e9rythropo\u00ef\u00e9tique d\u00e9riv\u00e9 de l'h\u00e9lice B de l'\u00e9rythropo\u00ef\u00e9tine humaine (Helix B Surface Peptide, HBSP) ; agoniste du r\u00e9cepteur inn\u00e9 de r\u00e9paration (IRR) ; codes de d\u00e9veloppement ARA-290 \/ cibinetide (Araim Pharmaceuticals)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formule mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>51<\/sub>H<sub>84<\/sub>N<sub>16<\/sub>O<sub>21<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~1 257,4 Da<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>S\u00e9quence<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">H-pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH (pyrEEQLERALNSS) \u2014 s\u00e9quence lin\u00e9aire de 11 r\u00e9sidus correspondant \u00e0 la face expos\u00e9e \u00e0 l'eau de l'h\u00e9lice B de l'\u00e9rythropo\u00ef\u00e9tine humaine. La glutamine N-terminale se cyclise spontan\u00e9ment en pyroglutamate (coh\u00e9rent avec la masse mol\u00e9culaire publi\u00e9e de 1 257,4 Da). Le C-terminal est un acide libre ; pas de pont disulfure, pas d'acylation d'acide gras, pas de PEGylation.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Poudre lyophilis\u00e9e (blanche \u00e0 blanc cass\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599 % (v\u00e9rifi\u00e9 par HPLC, COA sur demande)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C (r\u00e9frig\u00e9rateur) pour le stock de travail ; \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Reconstitu\u00e9 : 2\u20138 \u00b0C, utiliser dans les ~14\u201328 jours. Prot\u00e9ger de la lumi\u00e8re. \u00c9viter les cycles r\u00e9p\u00e9t\u00e9s de cong\u00e9lation-d\u00e9cong\u00e9lation de la solution reconstitu\u00e9e.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Eau bact\u00e9riostatique (recommand\u00e9e) ou eau st\u00e9rile. Tr\u00e8s soluble ; le 11-m\u00e8re non modifi\u00e9 se dissout rapidement avec un l\u00e9ger tourbillonnement.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que l'ARA-290 ?<\/h2>\n<p><strong>ARA-290<\/strong> (cibinetide) est un peptide synth\u00e9tique lin\u00e9aire de 11 acides amin\u00e9s correspondant \u00e0 la face expos\u00e9e \u00e0 l'eau de l'h\u00e9lice B de l'\u00e9rythropo\u00ef\u00e9tine humaine (EPO) \u2014 une r\u00e9gion de la mol\u00e9cule d'EPO qui n'est pas impliqu\u00e9e dans la liaison au r\u00e9cepteur homodim\u00e9rique classique de l'EPO (EPOR)<sub>2<\/sub>) qui stimule la production de globules rouges. L'ARA-290 a \u00e9t\u00e9 con\u00e7u de mani\u00e8re rationnelle par Michael Brines et Anthony Cerami chez Araim Pharmaceuticals pour dissocier deux activit\u00e9s pharmacologiques distinctes de l'EPO qui \u00e9taient historiquement entrelac\u00e9es dans une seule mol\u00e9cule : <strong>\u00e9rythropo\u00ef\u00e8se<\/strong> (l'effet d'augmentation de l'h\u00e9matocrite qui limite l'utilisation de l'EPO comme agent protecteur des tissus en raison du risque thromboembolique) et <strong>protection tissulaire<\/strong> (the anti-inflammatory, anti-apoptotic, and repair-promoting effects mediated by a distinct heteromeric receptor). By restricting the peptide sequence to the helix-B surface face, ARA-290 retains affinity for the <strong>r\u00e9cepteur inn\u00e9 de r\u00e9paration (IRR)<\/strong> \u2014 un h\u00e9t\u00e9rocomplexe compos\u00e9 de la sous-unit\u00e9 du r\u00e9cepteur de l'EPO (EPOR) et du r\u00e9cepteur b\u00eata commun (\u03b2cR, CD131 ; la sous-unit\u00e9 de signalisation partag\u00e9e des r\u00e9cepteurs du GM-CSF, de l'IL-3 et de l'IL-5) \u2014 tout en abolissant la liaison \u00e0 l'EPOR<sub>2<\/sub> homodimer responsible for erythropoiesis. The net effect is a peptide that produces EPO&#8217;s cytoprotective, anti-inflammatory, and neuroprotective effects in tissue without elevating hematocrit or carrying the thromboembolic and hypertensive risks that constrain therapeutic EPO use. ARA-290 has a short plasma half-life of approximately 2 minutes \u2014 the molecule is rapidly cleared \u2014 but the biological effect persists for 24\u201372 hours through downstream activation of cytoprotective signalling cascades (JAK2\/STAT3, PI3K\/Akt, anti-apoptotic Bcl-2 family upregulation). This pharmacokinetic profile is characteristic of receptor-trigger peptides where the duration of effect is driven by signal-cascade kinetics rather than by sustained plasma levels. ARA-290 has held <strong>statut de m\u00e9dicament orphelin<\/strong> in the United States and the European Union for sarcoidosis-associated small-fiber neuropathy, and has been evaluated in multiple Phase 2 clinical trials in diabetic neuropathy and sarcoidosis-associated neuropathic pain. <\/p>\n<h2>M\u00e9canisme d'action \u2014 Agonisme du r\u00e9cepteur inn\u00e9 de r\u00e9paration sans \u00e9rythropo\u00ef\u00e8se<\/h2>\n<p>What makes ARA-290 pharmacologically distinctive is that it activates the cytoprotective limb of erythropoietin signalling while bypassing the erythropoietic limb. Three mechanisms are documented in published studies:<\/p>\n<ul>\n<li><strong>Agonisme du r\u00e9cepteur de r\u00e9paration inn\u00e9e (IRR) \u2014 h\u00e9t\u00e9rocomplexe EPOR + \u03b2cR \/ CD131<\/strong> \u2014 Dans des conditions inflammatoires ou de l\u00e9sion hypoxique, les cellules tissulaires r\u00e9gulent \u00e0 la hausse le r\u00e9cepteur b\u00eata-commun (\u03b2cR, CD131) et forment un h\u00e9t\u00e9rocomplexe avec le r\u00e9cepteur de l'EPO (EPOR). Cet h\u00e9t\u00e9rocomplexe IRR est la cible mol\u00e9culaire de l'ARA-290. La liaison d\u00e9clenche la phosphorylation de JAK2 et l'activation en aval de STAT3 \/ STAT5 \/ PI3K-Akt, conduisant \u00e0 la r\u00e9gulation positive des prot\u00e9ines anti-apoptotiques (Bcl-2, Bcl-xL), \u00e0 la suppression de la production de cytokines pro-inflammatoires (TNF-\u03b1, IL-1\u03b2, IL-6) et au recrutement des programmes de r\u00e9paration tissulaire. Comme l'IRR est r\u00e9gul\u00e9 localement aux sites de l\u00e9sion ou d'inflammation plut\u00f4t qu'exprim\u00e9 de mani\u00e8re constitutive, l'ARA-290 agit comme un agoniste contextuel qui active la signalisation de r\u00e9paration sp\u00e9cifiquement l\u00e0 o\u00f9 elle est n\u00e9cessaire.<\/li>\n<li><strong>Aucune liaison \u00e0 l'EPOR homodim\u00e9rique<sub>2<\/sub> \u2014 pas d'\u00e9rythropo\u00ef\u00e8se<\/strong> \u2014 Le r\u00e9cepteur \u00e9rythropo\u00ef\u00e9tique classique sur les prog\u00e9niteurs \u00e9rythro\u00efdes de la moelle osseuse est un homodim\u00e8re de deux sous-unit\u00e9s EPOR sans implication du CD131. L'ARA-290 a une affinit\u00e9 n\u00e9gligeable pour cet homodim\u00e8re, ce qui explique pourquoi des doses r\u00e9p\u00e9t\u00e9es dans les essais cliniques ne produisent aucun changement d\u00e9tectable dans l'h\u00e9moglobine, l'h\u00e9matocrite ou le nombre de r\u00e9ticulocytes. C'est la caract\u00e9ristique centrale de conception qui distingue l'ARA-290 de l'EPO pleine longueur et des analogues ant\u00e9rieurs de l'EPO (darb\u00e9po\u00e9tine, CERA) qui conservaient une activit\u00e9 \u00e9rythropo\u00ef\u00e9tique.<\/li>\n<li><strong>Effets anti-inflammatoires et de r\u00e9paration tissulaire en aval<\/strong> \u2014 In preclinical and clinical studies, ARA-290 reduces pro-inflammatory cytokine production by activated macrophages, lowers neuropathic-pain scores in small-fiber neuropathy models, accelerates corneal wound healing, reduces ischemia-reperfusion injury in renal and cardiac models, and improves glycemic control in type 2 diabetes preclinical models. The breadth of effect reflects the broad tissue distribution of the IRR under inflammatory conditions rather than a tissue-specific mechanism.<\/li>\n<\/ul>\n<p>The short plasma half-life (~2 minutes) combined with sustained biological effect (24\u201372 hours) means ARA-290 protocols typically use daily or every-other-day dosing despite the rapid molecular clearance \u2014 the pharmacodynamic duration is set by the downstream signalling cascade, not by plasma residence. Subcutaneous administration is the standard administration route and the route used in clinical development. <\/p>\n<h2>Published Evidence<\/h2>\n<p>ARA-290 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Diabetic neuropathy and small-fiber neuropathy studies<\/strong> \u2014 corneal nerve-fiber density assessment, intra-epidermal nerve-fiber density (IENFD), neuropathic-pain scoring; lead clinical studies indication, with Phase 2 trials in type 2 diabetic neuropathy showing improvement in nerve-fiber regeneration and pain scores<\/li>\n<li><strong>Neuropathie des petites fibres associ\u00e9e \u00e0 la sarco\u00efdose<\/strong> \u2014 the indication for which ARA-290 holds US and EU orphan-drug designation; preclinical and Phase 2 studies in granulomatous inflammation models<\/li>\n<li><strong>Neuropathic pain studies<\/strong> \u2014 neuropathie p\u00e9riph\u00e9rique induite par la chimioth\u00e9rapie, neuropathie post-chirurgicale, dissection m\u00e9canistique des voies de la douleur m\u00e9di\u00e9es par IRR<\/li>\n<li><strong>Ischemia-reperfusion injury studies<\/strong> \u2014 mod\u00e8les d'isch\u00e9mie-reperfusion r\u00e9nale, cardiaque et c\u00e9r\u00e9brale ; caract\u00e9risation des effets anti-apoptotiques et anti-inflammatoires<\/li>\n<li><strong>Inflammation and innate immunity studies<\/strong> \u2014 polarisation des macrophages, tests de suppression des cytokines, dissection de la signalisation d\u00e9pendante vs ind\u00e9pendante de l'IRR<\/li>\n<li><strong>Type 2 diabetes metabolic support<\/strong> \u2014 contr\u00f4le glyc\u00e9mique, pr\u00e9servation des cellules b\u00eata, comparaison avec les m\u00e9canismes de sensibilisation \u00e0 l'insuline<\/li>\n<li><strong>Corneal wound-healing and ophthalmic studies<\/strong> \u2014 taux de fermeture des plaies \u00e9pith\u00e9liales corn\u00e9ennes, r\u00e9g\u00e9n\u00e9ration des fibres nerveuses dans la corn\u00e9e (l'un des tissus les plus dens\u00e9ment innerv\u00e9s et un indicateur sensible pour la r\u00e9paration m\u00e9di\u00e9e par IRR)<\/li>\n<\/ul>\n<p>For broader context on related anti-inflammatory and tissue-repair peptides, see <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a> (r\u00e9paration tissulaire MSK\/GI d\u00e9riv\u00e9e de peptides gastriques), <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a> (Fragment de Thymosine B\u00eata-4, r\u00e9paration tissulaire \u00e9tendue), et <a href=\"https:\/\/medsbase.com\/fr\/kpv-lysine-proline-valine\/\">KPV<\/a> (Tripeptide anti-inflammatoire d\u00e9riv\u00e9 de l'\u03b1-MSH). Parcouz l'int\u00e9gralit\u00e9 <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">catalogue de peptides<\/a> pour les compos\u00e9s associ\u00e9s. <\/p>\n<h2>Forces et concentrations disponibles<\/h2>\n<p>MedsBase stocks ARA-290 in 10 mg lyophilized vials calibrated to typical protocol lengths. Available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentration du flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 multi-week protocols across diabetic neuropathy, ischemia-reperfusion, corneal-repair, and inflammation models; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Clinical Phase 2 doses in published trials are 4 mg subcutaneous daily for diabetic neuropathy and sarcoidosis-associated neuropathy, so a single 10 mg pharmaceutical-grade vial represents a multi-day supply of clinical-equivalent dosing for in-vivo work. ARA-290 is supplied as the unmodified linear 11-mer \u2014 there is no acyl chain, no PEGylation, no disulfide bridge, and reconstitution is straightforward relative to longer or modified peptides. <\/p>\n<h2>Comparaison \u2014 ARA-290 vs BPC-157<\/h2>\n<p>L'ARA-290 et <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a> are both used in tissue-repair and anti-inflammatory studies, but the two peptides target entirely different molecular machinery. ARA-290 is an EPO-derived innate-repair-receptor agonist that drives JAK2\/STAT3 cytoprotective signalling. BPC-157 is a 15-amino-acid synthetic stable gastric pentadecapeptide derived from a fragment of human gastric juice protein BPC, acting through a complex multi-pathway mechanism including nitric oxide synthase modulation, VEGF upregulation, and growth-factor-receptor cross-talk. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">ARA-290<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">BPC-157<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Origine<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">H\u00e9lice B de l'\u00e9rythropo\u00ef\u00e9tine humaine (HBSP)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fragment de la prot\u00e9ine BPC du suc gastrique humain<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longueur<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">11 acides amin\u00e9s<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">15 acides amin\u00e9s<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>R\u00e9cepteur \/ cible<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">R\u00e9cepteur inn\u00e9 de r\u00e9paration (EPOR + \u03b2cR \/ CD131)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Multipathique : NO synthase, VEGF, interaction des facteurs de croissance<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Primary studies tissue<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nerf p\u00e9riph\u00e9rique, corn\u00e9e, tissu isch\u00e9mique, tissu inflammatoire<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Tendon, ligament, muqueuse intestinale, muscle<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Effet \u00e9rythropo\u00ef\u00e9tique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aucun (caract\u00e9ristique cl\u00e9 de conception)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">N\/A (pas un peptide de la voie EPO)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Demi-vie plasmatique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2 minutes (effet persiste 24\u201372 heures)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~30 minutes (biodisponibilit\u00e9 orale revendiqu\u00e9e en pr\u00e9clinique)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>D\u00e9veloppement clinique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Phase 2 (neuropathie diab\u00e9tique, SFN sarco\u00efdose) ; d\u00e9signation orpheline<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pr\u00e9clinique uniquement (aucun essai clinique majeur avec r\u00e9gulateur)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Modification<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">11-m\u00e8re lin\u00e9aire non modifi\u00e9<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">15-m\u00e8re lin\u00e9aire non modifi\u00e9 (sel d'ac\u00e9tate ou d'arginate stable)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on neuropathic-pain, peripheral-nerve regeneration, or IRR-mediated cytoprotection, ARA-290 is the targeted reference peptide. For studies focused on musculoskeletal tendon\/ligament repair or gastrointestinal mucosal healing, <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a> remains the more widely-studied option. The two peptides are sometimes combined in protocols that aim to recruit complementary repair pathways across both CNS\/peripheral-nerve tissue and connective tissue. See also <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a> (fragment de Thymosine B\u00eata-4, r\u00e9f\u00e9rence large pour la r\u00e9paration tissulaire) et <a href=\"https:\/\/medsbase.com\/fr\/kpv-lysine-proline-valine\/\">KPV<\/a> (tripeptide anti-inflammatoire d\u00e9riv\u00e9 de l'\u03b1-MSH). <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Besoin d'eau BAC ?<\/strong> La reconstitution de tout flacon lyophilis\u00e9 n\u00e9cessite de l'eau bact\u00e9riostatique st\u00e9rile. Associez ce produit \u00e0 notre <a href=\"\/fr\/bac-water\/\"><strong>Eau BAC (Eau bact\u00e9riostatique)<\/strong><\/a> \u2014 flacon multidose de 30 mL, pr\u00e9serv\u00e9 par 0,9 % d'alcool benzylique, qualit\u00e9 USP.<\/div>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> conserver les flacons lyophilis\u00e9s au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C dans leur emballage d'origine pour le stock de travail \u00e0 court terme. Pour le stockage \u00e0 long terme non ouvert, congeler \u00e0 \u221220 \u00b0C. L'ARA-290 lyophilis\u00e9 est stable sous r\u00e9frig\u00e9ration jusqu'\u00e0 24 mois et \u00e0 \u221220 \u00b0C jusqu'\u00e0 36 mois. \u00c9vitez les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation sur la poudre lyophilis\u00e9e. L'ARA-290 est un peptide lin\u00e9aire non modifi\u00e9 sans pont disulfure ni cha\u00eene acyle, donc sa manipulation est simple par rapport aux peptides structurellement complexes comme le cagrilintide ou le s\u00e9maglutide. <strong>Proc\u00e9dure de reconstitution :<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 10 mg vial, 2.0 mL of bacteriostatic water yields a 5 mg\/mL working concentration \u2014 0.08 mL delivers 400 mcg (a 1 mg dose requires 0.2 mL); 0.8 mL delivers a clinical-equivalent 4 mg dose. Swirl gently \u2014 do not shake vigorously, as foaming entrains air and can denature peptide chains. Allow the powder to dissolve fully (typically &lt;1 minute for ARA-290) before withdrawing. Once reconstituted, store the vial at 2\u20138 \u00b0C and use within 14\u201328 days. Protect from light. Discard if cloudiness, particulates, or colour change appears. <\/p>\n<h2>Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>L'ARA-290 est-il un analogue de l'EPO ? Augmente-t-il l'h\u00e9matocrite ?<\/h3>\n<p>L'ARA-290 est d\u00e9riv\u00e9 de l'h\u00e9lice B de l'\u00e9rythropo\u00ef\u00e9tine, mais il est con\u00e7u sp\u00e9cifiquement pour <em>re\u00e7oit pas<\/em> augmenter l'h\u00e9matocrite. L'effet \u00e9rythropo\u00ef\u00e9tique classique de l'EPO est m\u00e9di\u00e9 par le r\u00e9cepteur homodim\u00e9rique de l'EPO (EPOR<sub>2<\/sub>) sur les prog\u00e9niteurs \u00e9rythro\u00efdes de la moelle osseuse. L'ARA-290 se lie au r\u00e9cepteur h\u00e9t\u00e9rom\u00e9rique de r\u00e9paration inn\u00e9e (EPOR + \u03b2cR\/CD131) \u00e0 la place, et a une affinit\u00e9 n\u00e9gligeable pour l'EPOR<sub>2<\/sub>. Les essais de phase 2 publi\u00e9s ne montrent aucun changement dans l'h\u00e9moglobine, l'h\u00e9matocrite ou le nombre de r\u00e9ticulocytes apr\u00e8s des doses r\u00e9p\u00e9t\u00e9es. <\/p>\n<h3>Qu'est-ce que le r\u00e9cepteur de r\u00e9paration inn\u00e9e (IRR) ?<\/h3>\n<p>Le r\u00e9cepteur inn\u00e9 de r\u00e9paration est un h\u00e9t\u00e9rocomplexe constitu\u00e9 de la sous-unit\u00e9 du r\u00e9cepteur \u00e0 l'EPO (EPOR) et du r\u00e9cepteur b\u00eata-commun (\u03b2cR, \u00e9galement appel\u00e9 CD131 \u2014 la sous-unit\u00e9 de signalisation partag\u00e9e des r\u00e9cepteurs du GM-CSF, de l'IL-3 et de l'IL-5). L'IRR est r\u00e9gul\u00e9 \u00e0 la hausse localement sur les tissus stress\u00e9s, l\u00e9s\u00e9s ou enflamm\u00e9s plut\u00f4t qu'exprim\u00e9 de mani\u00e8re constitutive, ce qui explique pourquoi l'ARA-290 agit comme un signal de r\u00e9paration tissulaire contextuellement restreint plut\u00f4t que comme un agoniste syst\u00e9mique. <\/p>\n<h3>Pourquoi l'ARA-290 est-il \u00e9galement appel\u00e9 cibinetide ?<\/h3>\n<p>ARA-290 est le code de d\u00e9veloppement attribu\u00e9 par Araim Pharmaceuticals (le d\u00e9veloppeur original). Cibinetide est le DCI (d\u00e9nomination commune internationale) attribu\u00e9 ult\u00e9rieurement pour les contextes d'essais cliniques et r\u00e9glementaires. Les deux noms d\u00e9signent le m\u00eame peptide de 11 acides amin\u00e9s (CAS 1208243-50-8). <\/p>\n<h3>Pourquoi la demi-vie plasmatique est-elle si courte par rapport \u00e0 la dur\u00e9e de l'effet ?<\/h3>\n<p>L'ARA-290 a une demi-vie plasmatique d'environ 2 minutes \u2014 le peptide est rapidement \u00e9limin\u00e9 de la circulation \u2014 mais l'effet biologique persiste pendant 24 \u00e0 72 heures gr\u00e2ce \u00e0 l'activation en aval des cascades de signalisation JAK2\/STAT3, PI3K\/Akt et anti-apoptotique de la famille Bcl-2. Ce profil pharmacocin\u00e9tique est typique des peptides d\u00e9clencheurs de r\u00e9cepteurs o\u00f9 la dur\u00e9e est d\u00e9termin\u00e9e par la cin\u00e9tique de la cascade de signalisation plut\u00f4t que par des niveaux plasmatiques soutenus. <\/p>\n<h3>How does ARA-290 compare to BPC-157 for tissue repair studies?<\/h3>\n<p>Both peptides are used in tissue-repair studies but target different machinery and different tissues. ARA-290 acts via the innate repair receptor (EPOR + CD131) and is best-characterised in peripheral-nerve, corneal, and ischemic-tissue studies. <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a> acts through a multi-pathway mechanism involving nitric oxide synthase modulation and VEGF upregulation, and is best-characterised in tendon, ligament, gut mucosal, and muscle studies. Some protocols combine the two peptides to recruit complementary repair pathways. <\/p>\n<h3>Qu'est-ce que la neuropathie des petites fibres associ\u00e9e \u00e0 la sarco\u00efdose et pourquoi l'ARA-290 a-t-il re\u00e7u la d\u00e9signation orpheline pour cette indication ?<\/h3>\n<p>Sarcoidosis is a granulomatous inflammatory disease that produces a debilitating small-fiber neuropathy (SFN) in a substantial fraction of affected patients. ARA-290 holds US FDA and EU EMA orphan-drug designation for sarcoidosis-associated SFN, reflecting the rarity of the indication and the absence of other targeted treatments. The orphan designation supports clinical studies but does not constitute approval \u2014 ARA-290 is investigational at the time of this writing. <\/p>\n<h3>What is the standard dose for ARA-290?<\/h3>\n<p>Published Phase 2 clinical trials have used 2\u20134 mg subcutaneous daily for diabetic neuropathy and sarcoidosis-associated SFN. Preclinical animal studies have used wider dose ranges depending on model and tissue. Users should determine dose ranges from peer-reviewed literature appropriate to their specific protocol. <\/p>\n<h3>L'ARA-290 n\u00e9cessite-t-il une manipulation particuli\u00e8re en raison des modifications disulfure ou acyle ?<\/h3>\n<p>Non. L'ARA-290 est un peptide lin\u00e9aire de 11 acides amin\u00e9s non modifi\u00e9, sans pont disulfure, sans acylation d'acide gras et sans PEGylation. La reconstitution et la manipulation sont simples \u2014 un l\u00e9ger vortexage dissout la poudre lyophilis\u00e9e en ~1 minute. Comparez cela \u00e0 des peptides structurellement complexes comme le cagrilintide (cha\u00eene acyle + disulfure), le s\u00e9maglutide (cha\u00eene acyle) ou les peptides de la classe de l'insuline o\u00f9 la reconstitution n\u00e9cessite un \u00e9quilibrage plus long. <!-- medsbase-related-alts-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Peptide non \u00e9rythropo\u00ef\u00e9tique d\u00e9riv\u00e9 de l'EPO \u00e0 11 acides amin\u00e9s<br \/>\n\u2705 Agoniste du r\u00e9cepteur de r\u00e9paration inn\u00e9e (EPOR + CD131)<br \/>\n\u2705 Signalisation anti-inflammatoire, neuroprotectrice et de r\u00e9paration tissulaire<br \/>\n\u2705 Pas d'\u00e9l\u00e9vation de l'h\u00e9matocrite (caract\u00e9ristique cl\u00e9 de conception par rapport \u00e0 l'EPO compl\u00e8te)<br \/>\n\u2705 D\u00e9sign\u00e9 m\u00e9dicament orphelin pour la neuropathie des petites fibres associ\u00e9e \u00e0 la sarco\u00efdose<\/p>\n<p><strong>ARA-290<\/strong> contient un compos\u00e9 peptidique synth\u00e9tique.<\/p>","protected":false},"featured_media":71396,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6461,6462,5441],"class_list":["post-71388","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-ara-290","product_tag-cibinetide","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/71388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=71388"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/71396"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=71388"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=71388"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=71388"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=71388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}